GPX2 and colorectal carcinoma: As a result, we speculate that expression of GPX2 could serve as a marker for the degree of polyp malignancy, and that inhibitors of GPX enzymes—such as tiopronin52—may be relevant treatment strategies for CRC or premalignant lesions.